Mylan launches generic asthma treatment at 70% discount

Mylan launched its generic version of GlaxoSmithKline's asthma treatment Advair at a price 70 percent lower than the branded treatment, according to Reuters.

The treatment, approved in January, is the first generic of Advair to hit the market. It will be priced between $93.71 and $153.14.

The FDA didn't approve Advair generics from Novartis and Hikma Pharmaceuticals.